These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37684380)

  • 1. Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch.
    Liao Y; Liu L; Yang J; Zhou X; Teng X; Li Y; Wan Y; Yang J; Shi Z
    Sci Rep; 2023 Sep; 13(1):14812. PubMed ID: 37684380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Qu Y; Song YY; Chen CW; Fu QC; Shi JP; Xu Y; Xie Q; Yang YF; Zhou YJ; Li LP; Xu MY; Cai XB; Zhang QD; Yu H; Fan JG; Lu LG
    Clin Transl Gastroenterol; 2021 Apr; 12(4):e00323. PubMed ID: 33848277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study on FibroTouch and multi-parameter model for diagnosis of hepatic fibrosis in patients with chronic liver disease].
    Wang R; Ren W; Zhao S; Niu X; Tan P; Du H; Nan Y
    Zhonghua Gan Zang Bing Za Zhi; 2015 Apr; 23(4):265-9. PubMed ID: 26133817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
    Amernia B; Moosavy SH; Banookh F; Zoghi G
    BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gamma-Glutamyl Transpeptidase-to-Platelet ratio predicts liver fibrosis in patients with concomitant chronic hepatitis B and nonalcoholic fatty liver disease.
    Luo J; Du Z; Liang D; Li M; Yin Y; Chen M; Yang L
    J Clin Lab Anal; 2022 Aug; 36(8):e24596. PubMed ID: 35808928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
    Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
    Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease.
    Zhu SH; Zheng KI; Hu DS; Gao F; Rios RS; Li G; Li YY; Byrne CD; Targher G; Chen YP; Zheng MH
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):430-435. PubMed ID: 32398489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic value of liver stiffness measurement for the evaluation of liver fibrosis in nonalcoholic fatty liver].
    Ning J; Yao MJ; Liu SH; Zhou GD; Zhang Y; Li MY; Wang LJ; Wang L; Zhao JM; Lu FM
    Zhonghua Gan Zang Bing Za Zhi; 2020 Jul; 28(7):567-572. PubMed ID: 32791791
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
    Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
    Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
    Lavynenko O; Abdul-Ghani M; Alatrach M; Puckett C; Adams J; Abdelgani S; Alkhouri N; Triplitt C; Clarke GD; Vasquez JA; Li J; Cersosimo E; Gastaldelli A; DeFronzo RA
    Diabetes Obes Metab; 2022 May; 24(5):899-907. PubMed ID: 35014145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation of liver stiffness measured by FibroTouch and FibroScan with Ishak fibrosis score in patients with chronic hepatitis B].
    Chen GF; Ping J; Gu HT; Zhao ZM; Zhou Y; Xing F; Tao YY; Mu YP; Liu P; Liu CH
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):145-150. PubMed ID: 28297803
    [No Abstract]   [Full Text] [Related]  

  • 15. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
    Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
    Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening.
    Poustchi H; Alaei-Shahmiri F; Aghili R; Nobarani S; Malek M; Khamseh ME
    Arch Iran Med; 2021 Mar; 24(3):177-186. PubMed ID: 33878875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of the clinical value of ultrasound attenuation parameters in evaluating liver steatosis degree in patients with chronic liver disease].
    Qiao J; Zhao W; Du JH; Zhang SY; Wang RQ; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):876-881. PubMed ID: 33105934
    [No Abstract]   [Full Text] [Related]  

  • 18. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
    Petta S; Vanni E; Bugianesi E; Di Marco V; Cammà C; Cabibi D; Mezzabotta L; Craxì A
    Liver Int; 2015 May; 35(5):1566-73. PubMed ID: 24798049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis.
    Yang XZ; Gen AW; Xian JC; Xiao L
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):479-485. PubMed ID: 29424906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
    Yu XY; Song XX; Tong YL; Wu LY; Song ZY
    Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.